Traditional Chinese medicine with effect of resisting autoimmune thyroiditis and application of traditional Chinese medicine

Abstract

The invention belongs to the field of medicines, and relates to a traditional Chinese medicine with an effect of resisting autoimmune thyroiditis and application of the traditional Chinese medicine. The traditional Chinese medicine comprises tripterygium wilfordii as an effective component after ganoderma lucidum fermentation. The invention proves that the fermented tripterygium wilfordii has a treatment effect on autoimmune thyroiditis, the toxicity of the tripterygium wilfordii is reduced (the toxicity is reduced by about 41.7%), and the drug effect of the fermented tripterygium wilfordii is basically the same as that of the tripterygium wilfordii (the drug effect is maintained by more than 80%), so that the application value is higher.

Description

Technical Field

[0001] The invention belongs to the field of medicines and relates to a traditional Chinese medicine having the efficacy of resisting autoimmune thyroiditis and application thereof. Background Art

[0002] Autoimmune thyroiditis (AIT) is the most common autoimmune disease and the most common pathological state of the thyroid gland. It is caused by immune system disorders that lead to immune attacks on the thyroid gland. It is a T-cell-mediated organ-specific autoimmune disease. Hashimoto's thyroiditis (HT) is a classic type of AIT. Clinically, HT is the most common in AIT, and the significant increase in serum thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels is the most significant diagnostic indicator of the disease. At present, the cause of HT is not fully understood, and there is no special treatment in clinical practice. After the clinical diagnosis of HT, whether to treat it depends on the size of the thyroid gland and the presence or absence of symptoms. If the thyroid gland is not obviously enlarged and there are no obvious compression symptoms, it can be followed up and observed without treatment; for those with thyroid function changes, it is limited to adjusting the thyroid hormone level. Since this disease is an autoimmune disease, it can be treated from the perspective of immune regulation. In recent years, several scholars have used biological and gene therapy, immunomodulators, and traditional Chinese medicine to treat HT, which has achieved certain results, but further evidence-based medicine is needed.

[0003] Triperygium wilfordii Hook (TW) is a plant of the family Celastraceae. Its roots, stems and flowers are all toxic. The medicinal part is the root woody body with the second layer of bark removed. The Southern Yunnan Materia Medica written by Lan Mao in the Ming Dynasty records that it "enters the liver and spleen meridians and circulates the twelve meridians", and is also known as "purple gold bark"; the Compendium of Materia Medica also has a detailed description and textual records: Triperygium wilfordii is bitter, pungent and warm in nature, and has the functions of promoting blood circulation and removing addiction, clearing away heat and detoxifying, dispelling wind and dampness, reducing swelling and relieving pain, and killing insects and relieving itching. In recent years, studies have found that Triperygium wilfordii has anti-inflammatory, immune, anti-fertility, anti-tumor, and antibacterial activities. In recent years, it has been widely used to treat a variety of autoimmune diseases such as rheumatoid arthritis, glomerulonephritis, and lupus erythematosus. However, there are few reports on the study of Triperygium wilfordii in the treatment of autoimmune thyroiditis.

[0004] Modern pharmacological research has shown that Tripterygium wilfordii has a strong nonspecific anti-inflammatory effect, which takes effect slightly faster than corticosteroids and non-helicobacterial anti-inflammatory agents. It also has an immunomodulatory effect mainly based on immunosuppression, and can act on two major pathological links at the same time. Its possible mechanism is to inhibit the hyperactive humoral immune response by directly inhibiting the rapidly proliferating immune active cells such as B cells and Th cells, including inhibiting the production of autoantibodies, alleviating or blocking the inflammatory process of tissues (such as synovial membrane, glomerular basement membrane, thyroid gland, etc.) caused by immune response, and has a comprehensive effect of antagonizing inflammatory mediators, reducing vascular permeability, reducing exudation, edema, etc., so that clinical symptoms and signs can be relieved and improved more quickly.

[0005] Although Tripterygium wilfordii has shown some potential in the treatment of autoimmune diseases, its application still needs to be cautious. The toxic components of Tripterygium wilfordii include alkaloids, triterpenes, etc., which may cause adverse reactions while exerting therapeutic effects. Therefore, when using Tripterygium wilfordii for treatment, the dosage must be strictly controlled and the patient's liver and kidney function and blood indicators must be closely monitored to prevent potential toxic reactions.

[0006] In summary, as a drug with potential therapeutic value, Tripterygium wilfordii shows certain prospects in the treatment of Hashimoto's thyroiditis. However, its application still needs to be carried out under strict medical supervision to ensure efficacy and drug safety. Summary of the invention

[0007] Based on the above background, the present invention conducts animal experiments on the efficacy of Tripterygium wilfordii and fermented Tripterygium wilfordii, confirming the therapeutic effects of Tripterygium wilfordii and fermented Tripterygium wilfordii on autoimmune thyroiditis. While fermented Tripterygium wilfordii reduces the toxicity of Tripterygium wilfordii (the toxicity is reduced by about 41.7%), its efficacy is basically the same as that of Tripterygium wilfordii (the efficacy is maintained at more than 80%), so the present invention is proposed.

[0008] The invention provides a traditional Chinese medicine with the effect of resisting autoimmune thyroiditis, which comprises Ganoderma lucidum (preferably blood Ganoderma lucidum or bonsai Ganoderma lucidum) and Tripterygium wilfordii as an effective component.

[0009] Specifically, the preparation method of Ganoderma lucidum such as blood Ganoderma lucidum or bonsai Ganoderma lucidum after fermentation of Tripterygium wilfordii is as follows: the fermented seed liquid of Ganoderma lucidum is inoculated into Tripterygium wilfordii matrix, after standing and fermenting, the fermentation product is taken out and dried to obtain;

[0010] More specifically, the fermented seed liquid of Ganoderma lucidum is inoculated into the matrix of Tripterygium wilfordii under sterile conditions according to the ratio of 100g of Tripterygium wilfordii crushed material to 50-150mL of seed liquid. After fully mixing, the mixture is allowed to ferment at 23-25°C and 60-70% humidity for 15-30 days, then the fermentation is stopped, and the fermentation product is taken out, the surface of which is covered with white mycelium, and the product is dried at 50-70°C, preferably at 60°C.

[0011] The present invention also provides a fermentation method for preparing Tripterygium wilfordii with the efficacy of preventing autoimmune thyroiditis, which comprises the following steps:

[0012] (1) Preparation of Tripterygium wilfordii matrix: crushing Tripterygium wilfordii and sterilizing with high pressure steam to obtain Tripterygium wilfordii matrix;

[0013] (2) Bidirectional solid fermentation: The fermented seed liquid of the Ganoderma lucidum strain is inoculated into the Tripterygium wilfordii matrix of step (1), and after static fermentation, the fermentation product is taken out and dried.

[0014] Preferably, the Ganoderma lucidum strain in step (2) is selected from Ganoderma lucidum or Ganoderma lucidum bonsai.

[0015] Specifically, in the step (1), peeled Tripterygium wilfordii root slices are selected and mechanically coarsely crushed to less than 20 mesh; the high-pressure steam sterilization conditions of the step (1) are 110-130° C., 10-40 min; preferably 121° C., 30 min.

[0016] More specifically, the preparation of the fermented seed liquid of the Ganoderma lucidum strain in step (2) should be as follows:

[0017] (a) Strain activation treatment: Ganoderma lucidum strains were cultured on PDA plates to obtain seed plates;

[0018] (b) preparing the seed solution, taking the activated culture bacteria block on the plate in step (a), placing it in a PDB liquid culture medium for culture, and obtaining a fermentation seed solution;

[0019] More specifically, in step (a), a small piece of culture is scraped from the Ganoderma lucidum culture slant test tube and placed on a PDA plate, and the culture conditions are 28° C. and 60% humidity for 3-5 days, preferably 4 days;

[0020] The step (b) is to take the activated culture bacteria block on the plate of step (a), place it in PDB liquid culture medium, and culture it at 28° C. and 200 rpm for 5-7 days, preferably 6 days.

[0021] Specifically, in step (2), 100 g of the crushed Tripterygium wilfordii is inoculated with 50-100 mL of seed solution, the mixture is fully mixed, and then fermented at 23-25° C. and 60-70% humidity;

[0022] The fermentation period of step (2) is 15-30 days, preferably 18-22 days, more preferably 21 days;

[0023] The drying in step (4) is performed at 50-70°C, preferably at 60°C.

[0024] The present invention also provides the tripterygium wilfordii with anti-autoimmune thyroiditis efficacy obtained by the method.

[0025] The present invention further provides the use of the Tripterygium wilfordii having anti-autoimmune thyroiditis efficacy in the preparation of anti-autoimmune thyroiditis products. Specifically, the product is a medicine, food, health product or feed, or an additive thereof.

[0026] Since the present invention provides fermented tripterygium wilfordii as a traditional Chinese medicine, it can have a therapeutic effect on autoimmune thyroiditis and greatly reduce the toxicity of tripterygium wilfordii, and therefore has great application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The target organ toxicity of zebrafish after treatment with different Tripterygium wilfordii samples (n=30) is shown.

[0028] Figure 2 The pharmacodynamic evaluation indicators (TPOAb, TgAb) of Tripterygium wilfordii and fermented Tripterygium wilfordii are shown.

[0029] Figure 3 Shows the inflammatory cell evaluation of Tripterygium wilfordii and fermented Tripterygium wilfordii.

[0030] Figure 4 Detection of general and safety indicators of Tripterygium wilfordii and fermented Tripterygium wilfordii.

[0031] Figure 5 Pharmacodynamic evaluation of Tripterygium wilfordii and fermented Tripterygium wilfordii (thyroid pathology HE staining). DETAILED DESCRIPTION

[0032] The present invention is described below through specific implementation modes in order to better understand the present invention, but it does not constitute a limitation of the present invention.

[0033] Example 1: Preparation of fermented Tripterygium wilfordii

[0034] Materials: Tripterygium wilfordii slices, Ganoderma species (Ganoderma lucidum, Latin name: American Ganoderma, Latin name: Ganoderma oregonense; Ganoderma tsugae, Latin name: Ganoderma tsugae), Ganoderma rudeum, Latin name: Amauroderma rude, zebrafish, incubator, liquid chromatograph, mass spectrometer, rotary evaporator, spray dryer, etc.

[0035] 1. Processing method of Tripterygium wilfordii by fermentation and detoxification

[0036] (1) Preparation of Tripterygium wilfordii matrix: Mechanically coarsely crush the peeled Tripterygium wilfordii slices to ensure uniform size and crush them to less than 20 mesh; place the crushed material in a conical bottle and sterilize it with high pressure steam at 121° C. for 30 minutes to obtain the Tripterygium wilfordii matrix;

[0037] (2) Activation of strains: In a clean bench, a small piece of culture was scraped from the slant test tube of Ganoderma lucidum culture and placed on a PDA plate at 28°C and 60% humidity for 4 days to obtain a seed plate;

[0038] (3) Seed solution preparation: Take about 1 cm of the activated culture on the seed plate. 2 The bacterial blocks of different sizes were placed in 50 mL of PDB liquid culture medium and cultured at 28°C, 200 rpm for 6 days to obtain the fermentation seed liquid;

[0039] (4) The fermented seed liquid was inoculated into the Tripterygium wilfordii matrix in an ultra-clean work environment at a ratio of 50 g of Tripterygium wilfordii crushed material to 50 mL of seed liquid. After being fully mixed, the mixture was allowed to ferment at 23-25° C. and 60-70% humidity for 21 days. The fermentation was then stopped and the fermentation product was taken out. The surface of the fermentation product was covered with white mycelium and dried at 60° C.

[0040] The fermentation product was post-processed and the quality evaluation was performed as follows:

[0041] Liquid chromatography-mass spectrometry detection of the active ingredients of the fermentation product: take a certain amount of fermentation drying product, add 10 times the volume (mass: volume) of 75% ethanol to fully soak and extract, repeat 3 times, then combine the extracts for concentration, concentrate to 1 times the volume equivalent of the product, and then perform liquid chromatography-mass spectrometry detection.

[0042] Combined with the liquid chromatography-mass spectrometry detection results, the fermentation quality can be reasonably evaluated.

[0043] Toxicity testing of fermentation products: Take a certain amount of fermentation dried product, add 10 times the volume (mass: volume) of distilled water to fully soak and extract, repeat 3 times, then combine the extracts and concentrate to 10 times the volume equivalent of the product, and then spray dry; use the zebrafish animal model to observe its hatching rate and liver toxicity at specific concentrations.

[0044] 2. Effect of Ganoderma lucidum strains on the toxicity reduction of Tripterygium wilfordii

[0045] Using the above process, 50g of Tripterygium wilfordii matrix was inoculated with different Ganoderma lucidum strains for bidirectional solid fermentation, and the crude drug inoculated with sterile water was used as the control group.

[0046] After the fermentation is completed, the toxicity comparison of the processed Tripterygium wilfordii is carried out. In order to be as consistent as possible with the clinical medication form, the toxicity evaluation is performed by extracting the fermentation product with distilled water and concentrating it to a relative density of more than 1.05. Finally, it is spray-dried to obtain the fermented and processed Tripterygium wilfordii powder.

[0047] Wild-type AB zebrafish at 1-1.5h post-fertilization (1-1.5hpf) were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The samples were given water-soluble, and the concentration of water-soluble Tripterygium wilfordii powder was 500μg / mL. A normal control group and a solvent control group were set up at the same time, and the volume of each well was 3mL. The treatment was carried out at 28℃ for 5 days, and the number of zebrafish deaths in each experimental group was counted every day and the dead zebrafish were removed in time. Finally, statistical analysis was performed to calculate the LC of the samples. 50 , the results are shown in Table 1 below.

[0048] Table 1. Acute toxicity results of processed Tripterygium wilfordii on zebrafish

[0049] TW TW-XZ TW-PJ TW-MD TW-SS <![CDATA[LC 50 (μg / mL)]]> 829 1175 887 634 523 <![CDATA[R 2 ]]> 0.991 0.999 1.00 0.999 0.995

[0050] Note: TW is the crude drug control of Tripterygium wilfordii, TW-XZ is the fermentation group of Tripterygium wilfordii and Ganoderma lucidum, TW-PJ is the fermentation group of Tripterygium wilfordii and Ganoderma lucidum bonsai, TW-MD is the fermentation group of Tripterygium wilfordii and Ganoderma lucidum, TW-SS is the fermentation group of Tripterygium wilfordii and Ganoderma lucidum pine.

[0051] In order to explore the target organs of toxicity of Tripterygium wilfordii before and after fermentation, and whether the target organ toxicity can be effectively reduced after fermentation, we took the highest two concentrations of each sample within the concentration range with a mortality rate of <50% for evaluation. The specific target organs evaluated included the liver, kidney, intestine, heart, etc. We found that among all the target organs of zebrafish embryos, liver damage was the most important organ damage at all concentrations (250 / 500μg / mL), and the liver damage was mainly manifested as liver loss and delayed yolk sac absorption. Compared with the crude drug of Tripterygium wilfordii, among all groups of fermented Tripterygium wilfordii, the liver loss rate of Tripterygium wilfordii fermented with bonsai ganoderma lucidum was the lowest, followed by Tripterygium wilfordii fermented with blood ganoderma lucidum, which were 4.2 times and 2.2 times lower than that of the crude drug of Tripterygium wilfordii ( Figure 1 ).

[0052] The above results show that the median lethal concentration (LC50) of the control group of Tripterygium wilfordii 50 ) was 829 μg / mL, and the LC of TW-XZ 50 The liver is the main target organ of toxicity of Tripterygium wilfordii and fermented Tripterygium wilfordii ( Figure 1 ), TW-PJ had the greatest toxicity in reducing liver damage (Table 2).

[0053] The results showed that Tripterygium wilfordii showed obvious attenuation effect after fermentation with Ganoderma lucidum and Ganoderma bonsai, among which Ganoderma lucidum had the best attenuation effect. The subsequent experiments adopted the process of Example 1, took 50g of Tripterygium wilfordii matrix, inoculated Ganoderma lucidum and Ganoderma bonsai in proportion, and carried out two-way solid fermentation to obtain fermented Tripterygium wilfordii for drug efficacy evaluation.

[0054]

[0055] Example 2: Evaluation of the efficacy of fermented Tripterygium wilfordii

[0056] 120 healthy female / male NOD.H-2h4 mice, 7 weeks old, were introduced from Jackson Laboratory, USA. They were bred to the number required for the experiment. The mice were housed in single cages under specific pathogen-free (SPF) conditions. The ambient temperature was controlled at 22-25°C, the humidity was 55±5%, the light-dark cycle was 12 / 12 hours (lighting time was 7:00-19:00), and food and water were freely available. Establishment of autoimmune thyroiditis model: After one week of adaptive feeding, the 120 7-week-old NOD.H-2h4 mice used in the experiment were divided into a normal control group and an autoimmune thyroiditis model group. The normal control group was given normal drinking water, and the autoimmune thyroiditis model group was given 0.05% NaI to drink freely for 8 weeks. The model was verified after 8 weeks. After the model was successfully established, the model group was divided into 11 groups, namely, model group, low-, medium- and high-dose groups of Tripterygium wilfordii (TW), low-, medium- and high-dose groups of Tripterygium wilfordii bonsai and Ganoderma lucidum fermentation products (TW-PJ), low-, medium- and high-dose groups of Tripterygium wilfordii blood and Ganoderma lucidum fermentation products (TW-XZ) and Tripterygium wilfordii polyglycosides group, with 10 mice in each group.

[0057] Drug intervention: Drug administration for 2 months. (1) Blank control group: sterile drinking water, gavage with an equal volume of sterile drinking water, once a day. (2) EAT model group: sterile drinking water, gavage with an equal volume of sterile drinking water, once a day. (3) Low-dose group of Tripterygium wilfordii aqueous extract: sterile drinking water, gavage with 0.77125 g / kg / d of Tripterygium wilfordii aqueous extract, once a day. (4) Medium-dose group of Tripterygium wilfordii aqueous extract: sterile drinking water, gavage with 1.5425 g / kg / d of Tripterygium wilfordii aqueous extract, once a day. (5) High-dose group of Tripterygium wilfordii aqueous extract: sterile drinking water, gavage with 3.085 g / kg / d of Tripterygium wilfordii aqueous extract, once a day. (6) Low-dose group of XZ Tripterygium wilfordii aqueous extract: sterile drinking water, gavage with 0.77125 g / kg / d of fermented Tripterygium wilfordii aqueous extract, once a day. (7) XZ medium-dose group of Tripterygium wilfordii water extract: sterile drinking water, 1.5425 g / kg / d of fermented Tripterygium wilfordii water extract gavage, once a day. (8) XZ high-dose group of Tripterygium wilfordii water extract: sterile drinking water, 3.085 g / kg / d of fermented Tripterygium wilfordii water extract gavage, once a day. (9) PJ low-dose group of Tripterygium wilfordii water extract: sterile drinking water, 0.77125 g / kg / d of fermented Tripterygium wilfordii water extract gavage, once a day. (10) PJ medium-dose group of Tripterygium wilfordii water extract: sterile drinking water, 1.5425 g / kg / d of fermented Tripterygium wilfordii water extract gavage, once a day. (11) PJ high-dose group of Tripterygium wilfordii water extract: sterile drinking water, 3.085 g / kg / d of fermented Tripterygium wilfordii water extract gavage, once a day. (12) Tripterygium wilfordii polyglycosides group: Sterile drinking water, Tripterygium wilfordii polyglycosides tablets dissolved in water and administered orally once a day.

[0058] Index observation and detection: (1) Body weight: The weight of the mice was weighed and recorded using an electronic weighing machine, once a week. (2) Post-sample detection: (serum TPO, TgAb, ALT, AST, Cr detection, flow cytometry, pathological detection): After the last administration, fast for 12 hours and anesthetize with ether. Within 15 minutes, blood was collected through the ophthalmic artery and the serum was centrifuged for detection. Fresh thyroid tissue was collected for flow cytometry. The remaining thyroid tissue was fixed in 5% paraformaldehyde fixative for HE staining. Data analysis: For normally distributed data, ANOVA (multiple group test) and Student's t-test (two-group test) were used for analysis; for non-normally distributed data, Kruskal-Wallis H-test (multiple group test) and Mann-Whitney Utest (two-group test) were used for analysis.

[0059] Results: The TW low, medium and high dose groups, TW-XZ low, medium and high dose groups, TW-PJ low, medium and high dose groups, and Tripterygium wilfordii polyglycosides group all showed significant therapeutic effects. The main manifestations were the significant reduction of serum TPOAB and TgAb antibody levels ( Figure 2). (****(model group vs blank group): P<0.0001; #(drug administration group vs model group): P<0.05; ##(drug administration group vs model group): P<0.01; ###(drug administration group vs model group): P<0.001; ####(drug administration group vs model group): P<0.0001)

[0060] Spleen flow cytometry showed that the proportion of pro-inflammatory TH1 cells in the Tripterygium wilfordii polyglycosides, TW-XZ, and TW-PJ groups was significantly reduced ( Figure 3 )(**: P<0.01; #: P<0.05; ##: P<0.01); After simultaneous administration, the safety of each group (Cr, ALT, AST) was good, with no significant difference ( Figure 4 ). Pharmacodynamic experiments show that after the fermentation of blood ganoderma and bonsai ganoderma, Tripterygium wilfordii can maintain or approach the original efficacy (more than 80%). The general results show that there is no obvious weight change in mice after administration of Tripterygium wilfordii.

[0061] Pathological results showed that after administration, the thyroid structure of mice in each group changed from abnormal to complete, the follicle arrangement changed from disordered to neat, the colloid in the cavity began to be abundant, the diffuse lymphocyte infiltration gradually decreased, and the degree of thyroid immune inflammatory infiltration was reduced (thyroid HE staining) ( Figure 5 ).

[0062] Based on the above analysis, in the autoimmune thyroiditis mouse model, Tripterygium wilfordii showed good immunosuppressive activity, and after fermentation, Tripterygium wilfordii basically maintained good immunosuppressive activity.

Claims

1. A Chinese medicine having anti-autoimmune thyroiditis efficacy, characterized in that: The invention comprises Ganoderma lucidum (preferably blood Ganoderma lucidum or bonsai Ganoderma lucidum) and Tripterygium wilfordii as the effective ingredient.

2. The Chinese medicine according to claim 1, characterized in that The preparation method of Tripterygium wilfordii after fermentation of Ganoderma lucidum is as follows: the fermented seed liquid of Ganoderma lucidum is inoculated into Tripterygium wilfordii matrix, after standing for fermentation, the fermentation product is taken out and dried; More specifically, the fermented seed liquid of Ganoderma lucidum is inoculated into the matrix of Tripterygium wilfordii under aseptic conditions at a ratio of 100 g of crushed Tripterygium wilfordii to 50-150 mL of seed liquid, and after being fully mixed, the mixture is allowed to ferment at 23-25° C. and 60-70% humidity for 15-30 days, and then the fermentation is stopped. The fermentation product is taken out, the surface of which is covered with white mycelium, and the product is dried at 50-70° C., preferably at 60° C.

3. A fermentation method for processing Tripterygium wilfordii with the efficacy of resisting autoimmune thyroiditis, characterized in that: The following steps are involved: (1) Preparation of Tripterygium wilfordii matrix: crush the Tripterygium wilfordii and sterilize with high pressure steam to obtain the Tripterygium wilfordii matrix; (2) Bidirectional solid fermentation: The fermented seed liquid of the Ganoderma lucidum strain is inoculated into the Tripterygium wilfordii matrix of step (1), and after standing for fermentation, the fermentation product is taken out and dried.

4. The method according to claim 3, characterized in that: The Ganoderma lucidum strain in step (2) is selected from Ganoderma lucidum or Ganoderma lucidum bonsai.

5. The method according to claim 3, characterized in that: In the step (1), peeled Tripterygium wilfordii root slices are selected and mechanically coarsely crushed to less than 20 meshes; the high-pressure steam sterilization conditions of the step (1) are 110-130° C., 10-40 min; preferably 121° C., 30 min.

6. The method according to claim 3, characterized in that: The preparation of the fermented seed liquid of the Ganoderma lucidum species in step (2) should be as follows: (a) Strain activation treatment: Ganoderma lucidum strains were cultured on PDA plates to obtain seed plates; (b) preparing the seed solution, taking the activated culture bacteria block on the plate in step (a), placing it in a PDB liquid culture medium for culture, and obtaining a fermentation seed solution; More specifically, in step (a), a small piece of culture is scraped from the Ganoderma lucidum culture slant test tube and placed on a PDA plate, and the culture conditions are 28° C. and 60% humidity for 3-5 days, preferably 4 days; The step (b) is to take the activated culture bacteria block on the plate in step (a), place it in PDB liquid culture medium, and culture it at 28° C. and 200 rpm for 5-7 days, preferably 6 days.

7. The method according to claim 3, characterized in that: The step (2) is inoculating 100 g of the crushed Tripterygium wilfordii with 50-100 mL of seed solution, mixing thoroughly, and fermenting at 23-25° C. and 60-70% humidity; The fermentation period of step (2) is 15-30 days, preferably 18-22 days, more preferably 21 days; The drying in step (4) is performed at 50-70°C, preferably at 60°C.

8. Tripterygium wilfordii having anti-autoimmune thyroiditis efficacy obtained by the method according to any one of claims 3 to 7.

9. Use of the Tripterygium wilfordii having anti-autoimmune thyroiditis efficacy as claimed in claim 8 in the preparation of anti-autoimmune thyroiditis products.

10. The use according to claim 9, characterized in that The product is medicine, food, health product or feed, or an additive thereof.

Images